142 related articles for article (PubMed ID: 33163272)
1. The novel MET inhibitor, HQP8361, possesses single agent activity and enhances therapeutic efficacy of AZD9291 (osimertinib) against AZD9291-resistant NSCLC cells with activated MET.
Yu D; Li Y; Sun KD; Gu J; Chen Z; Owonikoko TK; Ramalingam SS; Sun SY
Am J Cancer Res; 2020; 10(10):3316-3327. PubMed ID: 33163272
[TBL] [Abstract][Full Text] [Related]
2. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer.
Jiang T; Zhou C
Transl Lung Cancer Res; 2014 Dec; 3(6):370-2. PubMed ID: 25806323
[TBL] [Abstract][Full Text] [Related]
3. Placenta-specific 8 is a potential novel target for osimertinib resistance in non-small cell lung cancer.
Fei X; Wang G; Shen H; Gu X
Oncol Lett; 2019 Jul; 18(1):955-961. PubMed ID: 31289574
[TBL] [Abstract][Full Text] [Related]
4. Protein tyrosine kinase 2: a novel therapeutic target to overcome acquired EGFR-TKI resistance in non-small cell lung cancer.
Tong X; Tanino R; Sun R; Tsubata Y; Okimoto T; Takechi M; Isobe T
Respir Res; 2019 Dec; 20(1):270. PubMed ID: 31791326
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1.
Deng Y; Ma G; Vallega KA; Wang D; Wang M; Wang C; Wang S; Ramalingam SS; Sun SY
Cancer Gene Ther; 2022 Nov; 29(11):1558-1569. PubMed ID: 35449204
[TBL] [Abstract][Full Text] [Related]
6. The selective c-Met inhibitor tepotinib can overcome epidermal growth factor receptor inhibitor resistance mediated by aberrant c-Met activation in NSCLC models.
Friese-Hamim M; Bladt F; Locatelli G; Stammberger U; Blaukat A
Am J Cancer Res; 2017; 7(4):962-972. PubMed ID: 28469968
[TBL] [Abstract][Full Text] [Related]
7. AZD9291 in epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Stinchcombe TE
Transl Lung Cancer Res; 2016 Feb; 5(1):92-4. PubMed ID: 26958499
[TBL] [Abstract][Full Text] [Related]
8. T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
Watanabe S; Yoshida T; Kawakami H; Takegawa N; Tanizaki J; Hayashi H; Takeda M; Yonesaka K; Tsurutani J; Nakagawa K
Mol Cancer Ther; 2017 Nov; 16(11):2563-2571. PubMed ID: 28839001
[TBL] [Abstract][Full Text] [Related]
9. Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Okabe T; Okamoto I; Tsukioka S; Uchida J; Hatashita E; Yamada Y; Yoshida T; Nishio K; Fukuoka M; Jänne PA; Nakagawa K
Clin Cancer Res; 2009 Feb; 15(3):907-13. PubMed ID: 19188161
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Della Corte CM; Malapelle U; Vigliar E; Pepe F; Troncone G; Ciaramella V; Troiani T; Martinelli E; Belli V; Ciardiello F; Morgillo F
Oncotarget; 2017 Apr; 8(14):23020-23032. PubMed ID: 28416737
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Hashida S; Yamamoto H; Shien K; Ohtsuka T; Suzawa K; Maki Y; Furukawa M; Soh J; Asano H; Tsukuda K; Miyoshi S; Kanazawa S; Toyooka S
Oncol Rep; 2015 Mar; 33(3):1499-504. PubMed ID: 25607753
[TBL] [Abstract][Full Text] [Related]
12. AZD9291 in TKI EGFR resistance in non-small cell lung cancer and the new concept of phase I trials.
Gil-Bazo I; Rolfo C
Transl Lung Cancer Res; 2016 Feb; 5(1):85-8. PubMed ID: 26958497
[TBL] [Abstract][Full Text] [Related]
13. The Third-Generation EGFR Inhibitor, Osimertinib, Promotes c-FLIP Degradation, Enhancing Apoptosis Including TRAIL-Induced Apoptosis in NSCLC Cells with Activating EGFR Mutations.
Shi P; Zhang S; Zhu L; Qian G; Ren H; Ramalingam SS; Chen M; Sun SY
Transl Oncol; 2019 May; 12(5):705-713. PubMed ID: 30856555
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study.
Wang W; Wang H; Lu P; Yu Z; Xu C; Zhuang W; Song Z
J Transl Med; 2019 Feb; 17(1):52. PubMed ID: 30791921
[TBL] [Abstract][Full Text] [Related]
15. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
[TBL] [Abstract][Full Text] [Related]
16. Impact of bevacizumab in combination with erlotinib on EGFR-mutated non-small cell lung cancer xenograft models with T790M mutation or MET amplification.
Furugaki K; Fukumura J; Iwai T; Yorozu K; Kurasawa M; Yanagisawa M; Moriya Y; Yamamoto K; Suda K; Mizuuchi H; Mitsudomi T; Harada N
Int J Cancer; 2016 Feb; 138(4):1024-32. PubMed ID: 26370161
[TBL] [Abstract][Full Text] [Related]
17. Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Hwang KE; Kwon SJ; Kim YS; Park DS; Kim BR; Yoon KH; Jeong ET; Kim HR
Exp Cell Res; 2014 May; 323(2):288-96. PubMed ID: 24631288
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations.
Wang Y; Singh R; Wang L; Nilsson M; Goonatilake R; Tong P; Li L; Giri U; Villalobos P; Mino B; Rodriguez-Canales J; Wistuba I; Wang J; Heymach JV; Johnson FM
Oncotarget; 2016 Jul; 7(30):47998-48010. PubMed ID: 27384992
[TBL] [Abstract][Full Text] [Related]
19. Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors.
Baldacci S; Mazieres J; Tomasini P; Girard N; Guisier F; Audigier-Valette C; Monnet I; Wislez M; Pérol M; Dô P; Dansin E; Leduc C; Giroux Leprieur E; Moro-Sibilot D; Tulasne D; Kherrouche Z; Labreuche J; Cortot AB
Oncotarget; 2017 Dec; 8(62):105103-105114. PubMed ID: 29285237
[TBL] [Abstract][Full Text] [Related]
20. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group.
Jiang T; Su C; Ren S; Cappuzzo F; Rocco G; Palmer JD; van Zandwijk N; Blackhall F; Le X; Pennell NA; Zhou C;
J Thorac Dis; 2018 Jul; 10(7):3909-3921. PubMed ID: 30174832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
